Akeso, Inc. (HK:9926)
:9926
Top Page
Akeso, Inc.
(9926)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$98.00
▼(-28.73% Downside)
Action:ReiteratedDate:02/03/26
The score is primarily weighed down by weak financial performance (profitability and cash flow pressures) and bearish technicals (below major moving averages with negative MACD). Valuation also provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Advanced manufacturing capabilities
Akeso's advanced manufacturing capabilities provide durable operational leverage: they enable commercial scale-up, contract manufacturing revenue, and faster supply for internal launches. This diversifies revenue streams, supports margin sustainability, and strengthens strategic partner appeal over time.
Negative Factors
Negative operating cash flow
Persistent negative operating cash flow reduces internal funding for trials and commercialization, increasing reliance on external financing. Over months this can constrain R&D pacing, dilute equity via capital raises, and pressure long-term investment unless cash generation reverses.
Read all positive and negative factors
Positive Factors
Negative Factors
Advanced manufacturing capabilities
Akeso's advanced manufacturing capabilities provide durable operational leverage: they enable commercial scale-up, contract manufacturing revenue, and faster supply for internal launches. This diversifies revenue streams, supports margin sustainability, and strengthens strategic partner appeal over time.
Read all positive factors
Akeso, Inc. (9926) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$126.66B
Dividend YieldN/A
Average Volume (3M)11.45M
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue Growth33.46%
EPS Growth-7.60%
CountryHK
Employees3,035
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.65
Shares Outstanding921,143,200
10 Day Avg. Volume8,237,327
30 Day Avg. Volume11,452,631
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)7.12
Price to Sales (P/S)22.84
P/FCF Ratio-43.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$168.57Price Target Upside22.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.29
Revenue Forecast (FY)HK$5.15B
Akeso, Inc. Business Overview & Revenue Model
Company Description
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GE...
How the Company Makes Money
Akeso, Inc. generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is based on several key streams, including direct sales of approved drugs, licensing agreements with ...
Akeso, Inc. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.51B | 2.12B | 4.53B | 837.66M | 225.63M | 0.00 |
| Gross Profit | 2.02B | 1.83B | 4.39B | 734.54M | 195.41M | -1.90M |
| EBITDA | -704.02M | -604.99M | 2.17B | -1.27B | -1.32B | -1.01B |
| Net Income | -846.01M | -514.51M | 2.03B | -1.17B | -1.07B | -1.04B |
Balance Sheet | ||||||
| Total Assets | 13.29B | 12.75B | 9.18B | 5.50B | 4.81B | 3.86B |
| Cash, Cash Equivalents and Short-Term Investments | 7.14B | 7.32B | 4.88B | 2.29B | 2.65B | 2.80B |
| Total Debt | 4.54B | 3.95B | 2.99B | 1.88B | 859.42M | 198.99M |
| Total Liabilities | 6.93B | 6.00B | 4.66B | 2.95B | 1.53B | 405.73M |
| Stockholders Equity | 6.44B | 6.81B | 4.69B | 2.64B | 3.16B | 3.19B |
Cash Flow | ||||||
| Free Cash Flow | -163.83M | -1.11B | 1.59B | -2.02B | -1.71B | -1.06B |
| Operating Cash Flow | -408.62M | -527.62M | 2.47B | -1.24B | -1.00B | -617.77M |
| Investing Cash Flow | -3.48B | -1.52B | -4.00B | -889.75M | -579.59M | -555.70M |
| Financing Cash Flow | 2.84B | 3.39B | 960.89M | 1.49B | 1.59B | 2.88B |
Akeso, Inc. Technical Analysis
Positive
137.50
Price Trends
111.76
Positive
114.94
Positive
123.90
Positive
Market Momentum
7.11
Negative
71.84
Negative
89.47
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9926, the sentiment is Positive. The current price of 137.5 is above the 20-day moving average (MA) of 119.81, above the 50-day MA of 111.76, and above the 200-day MA of 123.90, indicating a bullish trend. The MACD of 7.11 indicates Negative momentum. The RSI at 71.84 is Negative, neither overbought nor oversold. The STOCH value of 89.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9926.
Akeso, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$80.14B | 51.47 | 32.32% | ― | 46.14% | 39.56% | |
63 Neutral | HK$145.56B | 11.12 | 10.55% | ― | 16.90% | 63.11% | |
61 Neutral | HK$108.02B | 43.78 | 11.85% | 1.40% | 13.69% | 50.71% | |
61 Neutral | HK$154.95B | 144.97 | 4.82% | ― | 52.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$41.02B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
45 Neutral | HK$126.66B | -84.52 | -14.40% | ― | 33.46% | -7.60% |
* Healthcare Sector Average
HK:9926
Akeso, Inc.
137.50
66.35
93.25%
HK:1177
Sino Biopharmaceutical
6.04
2.69
80.14%
HK:1801
Innovent Biologics
89.30
47.10
111.61%
HK:2269
Wuxi Biologics (Cayman)
35.18
16.68
90.16%
HK:9995
RemeGen Co. Ltd. Class H
110.00
84.30
328.02%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
25.42
12.32
94.05%
Akeso, Inc. Corporate Events
Akeso Grants JumpCan Exclusive Mainland China Rights to Cholesterol Drug 伊喜寧®
Feb 3, 2026
Akeso, Inc. has granted Hubei JumpCan Pharmaceutical’s subsidiaries exclusive rights to commercialize its newly approved PCSK9 monoclonal antibody ebronucimab injection (伊喜寧®) in mainland China, in exchange for an R...
Akeso Details Long-Term MAb Contract Manufacturing and Demand Assumptions
Jan 26, 2026
Akeso, Inc. has provided additional details on its long-term contract manufacturing arrangement involving CTTQ-Akeso, Akeso Biopharma, Chai Tai Tianqing and Nanjing Tianqing, clarifying that the supplemental agreement for MAb product manufacturing...
Akeso Restructures MAb Manufacturing Deal as Joint Venture Becomes Connected Transaction
Dec 31, 2025
Akeso has updated the contractual framework governing the manufacturing of its monoclonal antibody products for its joint venture CTTQ-Akeso, which was established with partner Chia Tai Tianqing. Under a supplemental agreement effective 1 January ...
Akeso’s Innovative Drugs Included in China’s 2025 NRDL
Dec 7, 2025
Akeso, Inc. announced that all approved indications of its five marketed innovative drugs have been included in China’s 2025 National Reimbursement Drug List (NRDL), effective January 1, 2026. This inclusion is expected to enhance the compan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.